These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12384412)

  • 1. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation.
    Whartenby KA; Straley EE; Kim H; Racke F; Tanavde V; Gorski KS; Cheng L; Pardoll DM; Civin CI
    Blood; 2002 Nov; 100(9):3147-54. PubMed ID: 12384412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
    Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
    Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions.
    Pearl-Yafe M; Yolcu ES; Stein J; Kaplan O; Yaniv I; Shirwan H; Askenasy N
    Stem Cells; 2007 Jun; 25(6):1448-55. PubMed ID: 17363551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival.
    Min WP; Gorczynski R; Huang XY; Kushida M; Kim P; Obataki M; Lei J; Suri RM; Cattral MS
    J Immunol; 2000 Jan; 164(1):161-7. PubMed ID: 10605007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
    Drobyski WR; Majewski D
    Blood; 1997 Feb; 89(3):1100-9. PubMed ID: 9028343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-alphabeta.
    Lan F; Zeng D; Huie P; Higgins JP; Strober S
    Blood; 2001 Jun; 97(11):3458-65. PubMed ID: 11369637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice.
    Andersson G; Illigens BM; Johnson KW; Calderhead D; LeGuern C; Benichou G; White-Scharf ME; Down JD
    Blood; 2003 Jun; 101(11):4305-12. PubMed ID: 12576326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation.
    Hanash AM; Levy RB
    Blood; 2005 Feb; 105(4):1828-36. PubMed ID: 15494429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved mouse Sca-1+ cell-based bone marrow transplantation model for use in gene- and cell-based therapeutic studies.
    Hall SL; Lau KH; Chen ST; Felt JC; Gridley DS; Yee JK; Baylink DJ
    Acta Haematol; 2007; 117(1):24-33. PubMed ID: 17095856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.
    Davis JE; Harvey M; Gherardin NA; Koldej R; Huntington N; Neeson P; Trapani JA; Ritchie DS
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):242-9. PubMed ID: 25459639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells.
    Cui Y; Golob J; Kelleher E; Ye Z; Pardoll D; Cheng L
    Blood; 2002 Jan; 99(2):399-408. PubMed ID: 11781219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis.
    Jiang Z; Podack E; Levy RB
    Blood; 2001 Jul; 98(2):390-7. PubMed ID: 11435308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoblasts promote engraftment of allogeneic hematopoietic stem cells.
    El-Badri NS; Wang BY; Cherry ; Good RA
    Exp Hematol; 1998 Feb; 26(2):110-6. PubMed ID: 9472800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
    Askenasy N; Mizrahi K; Ash S; Askenasy EM; Yaniv I; Stein J
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.
    Pearl-Yafe M; Yolcu ES; Stein J; Kaplan O; Shirwan H; Yaniv I; Askenasy N
    Exp Hematol; 2007 Oct; 35(10):1601-12. PubMed ID: 17889725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW; Bohana-Kashtan O; Civin CI
    Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
    Marks L; Altman NH; Podack ER; Levy RB
    Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
    Komatsu M; Mammolenti M; Jones M; Jurecic R; Sayers TJ; Levy RB
    Blood; 2003 May; 101(10):3991-9. PubMed ID: 12521999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.